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Abstract
The acetylated fetal hemoglobin (AcHbF)
derives from an enzyme-mediated post-trans-
lational modification occurring on the N-ter-
minal glycine residues of g-chains. At present,
no established data are available on reference
intervals for AcHbF in newborns. A total of 92
healthy infants, with gestational age between
37 and 41 weeks were selected for the estab-
lishment of AcHbF reference intervals. Blood
samples were collected by heel pricking, when
collecting routine neonatal screening, and the
hemoglobin pattern was analyzed by high-per-
formance liquid chromatography. AcHbF
results were then normalized for HbF content
in order to account for differences in hemoglo-
bin switch. No difference was found in AcHbF
values between genders (P=0.858). AcHbF
results were as follow: 12.8±0.8% (mean±stan-
dard deviation), reference interval: 11.3-14.3%.
This finding could facilitate further studies
aimed to assess the possible use of AcHbF, for
instance as a possible fetal metabolic biomark-
er during pregnancy. 
Fetal hemoglobin in healthynewborns
Fetal hemoglobin (HbF) is the major hemo-
globin component at birth, and it is normally
replaced by hemoglobin A (HbA) in the first
year of life if no thalassemic syndromes are
present.1 Some authors indeed believe that the
expression of human globin genes reaches the
equilibrium after 2 years.2
HbF measurement is clinically useful in the
study and diagnosis of some important globin
gene disorders where HbF levels may vary con-
siderably (mainly, b- and db-thalassemia,
HPHF) and in a number of acquired conditions
associate with mild increases of HbF.3
Approximately 10-20% of HbF, either in fetal
than in adult blood, is present as a post-trans-
lational adduct, under the form of acetylated
derivative (AcHbF), produced by the acetyla-
tion of the N-terminal glycine residues of the g
chains,4,5 but there are inconsistent evidences
in the literature on how AcHbF may vary dur-
ing pregnancy. Probably, significant differ-
ences in the analytical methodologies
employed may explain part of the discrepan-
cies. Indeed, various methods such as ion
exchange, affinity chromatography, isoelectric
focusing and or spectrophotometry using thio-
barbaturic acid and liquid chromatography-
mass spectrometry have been used so far.6
Finally, AcHbF could be potentially used to eval-
uate possible hypoglycemic episodes in the
mother during pregnancy, because glycated
hemoglobin in newborn is hardly detectable.
Aim of our work was then to evaluate the
reference intervals of AcHbF in newborns in
order to provide a key for the interpretation of
possible laboratory findings, not only for
healthy newborns, but also with regard to new-
borns with various pathologies or at risk for
various pathologies due to the general condi-
tions of the mother during pregnancy.
A total of 166 newborns (78 males and 88
females, gestational age between 30 and 42
weeks) born at Del Ponte Hospital, Varese,
Italy, from October 2011 to July 2012, were
recruited. Out of that group, a total of 121 new-
borns (61 males and 50 females, gestational
age between 31 and 42 weeks) were studied, in
order to evaluate the relationship between
HbF, AcHbF, HbA and gestational age. For the
definition of the AcHbF reference interval, a
subgroup of 92 healthy infants [48 males with
gestational age between 37 and 42 weeks
(median/IQR: 39.0/1.1 weeks) and 44 females
with gestational age between 37 and 42 weeks
(median/IQR: 39.3/1.2 weeks)] with adequate
birth weight for gestational age was selected.
All of them were of Caucasian origin and pre-
sented negative neonatal, as well as gestation-
al anamnesis. Newborns of mothers with dia-
betes, impaired fasting glucose or impaired
glucose tolerance (both pre-existing and ges-
tational), as well known carriers of hemoglo-
binopathies were not included. Five mL blood
samples, left out from the routine neonatal
screening, were collected between the 2nd and
4th day of life by heel pricking and stored at
+4°C in a dedicated device (HbA1c Capillary
Collection System, Bio-Rad Laboratories,
Segrate, MI, Italy) until analysis. Hemoglobin
pattern was analyzed by high-performance liq-
uid chromatography (Variant II, Dual Kit, Bio-
Rad Lab.). 
A typical separation profile obtained from
the analysis of newborn blood is shown in
Figure 1. As it can be seen, the AcHbF is elut-
ing at a very early stage of the run, but its sep-
aration from the major HbF peak is fairly good.
With regard to the levels of HbA, HbF and
AcHbF in relation to gestational age, the data
we have obtained are reported in Figure 2. We
have not interpolated the data by any function,
but it is clearly evident that the decline in the
expression of HbF is in relation to the progres-
sive increase in HbA, due to the well know
switch in the expression of globin genes dur-
ing the development of the fetus. Overall there
is a significant dispersion of the points, but it
has already been shown that the switch can be
delayed or anticipated in different subjects, in
reason of possible polymorphisms or muta-
tions in various genes.7
However, if the correlations between these
hemoglobins measured at birth are analyzed,
what is obtained is reported in Figure 3. This
finding proves that, beside the variability in
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the expression of the globin switch between
different subjects as reported in Figure 2,
indeed the mechanism of the switch is highly
tuned in each subject, as already well known
since many years.8 For the evaluation of the
AcHbF reference interval, AcHbF results were
normalized for HbF content in order to account
for differences in hemoglobin switch, accord-
ing to the formula:
[AcHbFadj] = ([AcHbF]/ [AcHbF]+[HbF]) x 100 
No difference was found in AcHbFadj values
between genders (P=0.858) and the AcHbFadj
values were found to have a normal distribu-
tion (Shapiro-Wilk test, P=0.737). The overall
AcHbFadj results were: 12.8±0.8% (mean±stan-
dard deviation), and the reference interval
(2.5-97.5 centiles) were: 11.3-14.3%. No rele-
vant correlation between AcHbFadj and new-
born birth weight or length was found.
Conclusions
In conclusion, the reference intervals for
AcHbF have been defined in a well-character-
ized population of healthy newborns of not dia-
betic mothers. This finding could facilitate fur-
ther studies aimed to assess the possible use
of AcHbF as an index of fetal exposure to glu-
cose during pregnancy. 
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Figure 1. Typical high-performance liquid chromatography pro-
file obtained from the analysis of a blood sample from a new-
born.
Figure 3. Correlation between fetal hemoglobin (HbF) and HbA
measured at birth. 
Figure 2. Fetal hemoglobin (HbF), HbA (A) and acetylated fetal hemoglobin (AcHbF)
(B), in relation to gestational age (n=121). The dashed lines mark the physiologic deliv-
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